News & Updates
Filter by Specialty:
Adding cyclophosphamide to glucocorticoids confers no survival benefit in IPF
Adding cyclophosphamide to glucocorticoid treatment in patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) was associated with a numerically increased risk of mortality, according to results of the phase III EXAFIP trial.
Adding cyclophosphamide to glucocorticoids confers no survival benefit in IPF
24 Sep 2021
Tofacitinib may promote HBV reactivation in certain RA patients
Use of tofacitinib for rheumatoid arthritis (RA) may lead to reactivation of hepatitis B virus (HBV), especially among hepatitis B surface antigen-positive (HBsAg+) and HBsAg-negative/hepatitis B core antibody-positive (HBsAg–/HBcAb+) patients, according to a study from Taiwan.
Tofacitinib may promote HBV reactivation in certain RA patients
24 Sep 2021
MV130 immunotherapy prevents COPD exacerbations
Treatment with MV130, a sublingual bacterial immunotherapy, reduces the number of exacerbations in patients with chronic obstructive pulmonary disease (COPD), according to a recent study presented at ERS 2021.
MV130 immunotherapy prevents COPD exacerbations
24 Sep 2021
Doxycycline not recommended for COVID-19 outpatient treatment in older adults
Daily treatment with doxycycline did not shorten recovery time or reduce hospitalization or death in community-dwelling older adults with COVID-19, according to a study from the PRINCIPLE Collaborative Group.
